Medtronic has started 2026 strong in the first quarter with new FDA clearances and growth in the market.
Here are five headlines to know:
1. Medtronic earned the FDA’s 510(k) clearance for its Stealth AXiS system that brings planning, navigation and robotics into one spine platform.
2. Stealth AXiS earned additional FDA clearance for cranial as well as ear, nose and throat procedures.
3. Medtronic saw 8.7% year over year growth in the third quarter of fiscal year 2026, according to financial results posted Feb. 17.
4. Medtronic’s Infuse bone graft earned the FDA’s premarket approval for one- and two-level transforaminal lumbar interbody spinal fusions.
5. Medtronic’s spine components have been used in the majority of lumbar and cervical procedures from 2015 to 2024, according to the American Spine Registry’s 2026 Annual Report.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
